一項耗資 3,800 萬美元的新研究旨在測試常見藥物是否能延緩衰老並促進健康。
New $38 million study tests if common drugs can extend healthy aging
一項名為VITAL-H，耗資3800萬美元的開創性研究，正在挑戰我們對於變老（ㄅㄧㄢˋㄌㄠˇ）的看法。
A groundbreaking $38 million study called VITAL-H is challenging how we approach getting older.
這項臨床試驗由德州大學聖安東尼奧分校健康科學中心的Barshop研究所領導，旨在將醫學的重點從疾病出現後的治療，轉向更前瞻性的作法。
Led by the Barshop Institute at UT Health San Antonio, this clinical trial aims to move medicine beyond just treating diseases after they appear.
相反地，該研究的目標是透過測試現有且經FDA批准的藥物是否能減緩生物學上的老化，來主動改善「健康壽命」（我們維持健康狀態生活的年數）。
Instead, the goal is to proactively improve 'healthspan'—the number of years we live in good health—by testing if existing, FDA-approved medications can slow down biological aging.
在美國衛生高級研究計畫局（ARPA-H）的資助下，該研究將追蹤726名60至65歲的成年人。
Funded by the Advanced Research Projects Agency for Health (ARPA-H), the study will follow 726 adults between 60 and 65.
參與者將接受三種藥物測試：雷帕黴素（Rapamycin）、達格列淨（Dapagliflozin）和司美格魯肽（Semaglutide）。
Participants will be tested with three drugs: Rapamycin, Dapagliflozin, and Semaglutide.
其最終的抱負是縮小壽命與健康壽命之間的差距，確保我們在活得更久的同時，也能保持更獨立且充滿活力的狀態。
The ultimate ambition is to narrow the gap between our lifespan and our healthspan, ensuring that as we live longer, we also stay more independent and vibrant.
